Trial Profile
A Phase 2, Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Study to Compare the Safety and Efficacy of Tazarotene Lotion to Tazorac® (Tazarotene) Cream, in the Treatment of Acne Vulgaris
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Jul 2022
Price :
$35
*
At a glance
- Drugs Tazarotene (Primary) ; Tazarotene
- Indications Acne vulgaris
- Focus Therapeutic Use
- Sponsors Bausch Health Companies; Valeant Pharmaceuticals International
- 01 Jun 2022 Results assessing the dermal sensitization, safety, tolerability, and participant satisfaction data from five phase-1, -2, and -3 studies ( (phase-2 (NCT02938494) and two phase-3 studies (NCT03168334; NCT03168321))) of lower-dose tazarotene 0.045% polymeric emulsion lotion were published in the Journal of Dermatological Treatment.
- 23 Jun 2020 According to a Bausch Health Companies media release, Emil Tanghetti is the lead investigator of the study.
- 23 Jun 2020 Results published in the Bausch Health Companies Media Release.